Anemia Drugs For Cancer Patients Increase Risk Of Death
Posted on: Saturday, 2 May 2009, 07:31 CDT
Erythropoiesis-stimulating agents not recommended as routine therapy
The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ.
While the relative increased risk of death was only 15-16%, because of the high mortality rates in cancer patients this increase might translate into significant numbers of people.
"These findings suggest that erythropoiesis-stimulating agents should not be routinely used as an alternative to blood transfusion in patients with chemotherapy-induced anemia unless future studies document safety and clinical benefits in this population," write Dr. Marcello Tonelli from the University of Alberta and coauthors.
Anemia in cancer patients can develop because of the cancer itself or because of treatments such as chemotherapy. Treatment with agents to stimulate red blood cell formation has been widely used to improve quality of life for many patients and as an alternative to blood transfusions. However, these agents are expensive and reimbursement policies in Canada vary across provinces and territories.
The study, a meta-analysis of 52 clinical trials with 12,006 participants, was based on work done for the Canadian Agency for Drugs and Technologies in Health (CADTH) to summarize the benefits and harms of these agents in adults with cancer-related anemia.
The findings, which are consistent with studies from the United States and the United Kingdom, provide important information for clinicians treating cancer patients and for Canadian policy makers regarding drug reimbursement plans.
"Our findings suggest that existing practice guidelines should be revised to recommend against the routine use of erythropoiesis-stimulating agents as an alternative to blood transfusion in patients with cancer," conclude the authors. The authors add that erythropoiesis-stimulating agents may be warranted in situations where blood transfusions are not possible or practical.
---
On the Net:
Related Articles
- Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
- Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
- Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
- Leading Oncologists From Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients With Cancer
- Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology
- CMS Coverage Proposal for Erythropoiesis-Stimulating Agents (ESAs) Jeopardizes Cancer Clinical Practice and Patient Access
- Ortho Biotech in Discussions With FDA Regarding Prescribing Information for Erythropoiesis-Stimulating Agents
- Marrow Transplant Technique May Help Blood Cancer Patients
- Erythropoiesis-Stimulating Protein Therapy and the Decline of Renal Function: a Retrospective Analysis of Patients With Chronic Kidney Disease
- Blood-Cancer Drugs Do Well in Early Tests
 |
 |
User Comments (0)
RSS Feeds